Trial Profile

A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cell Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belinostat (Primary) ; Pralatrexate (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms CRESCENDO
Sponsors Acrotech Biopharma

10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
05 Nov 2023 Status changed from not yet recruiting to recruiting.
12 Oct 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com